Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Rituximab, bortezomib, modified hyper-cyclophosphamide, doxorubicin, vincristine, dexamethasone (VcR-CVAD) induction chemoimmunotherapy and maintenance rituximab (MR) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405. Patients with previously untreated mantl...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Chang, Julie E., Li, Hailun, Smith, Mitchell R., Gascoyne, Randy D., Paietta, Elisabeth M., Yang, David T., Advani, Ranjana H., Horning, Sandra J., Kahl, Brad S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2014
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3954048/
https://ncbi.nlm.nih.gov/pubmed/24458437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-08-523845
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky